In Brief: CDC calls for safer cough/cold delivery, USPlabs toes the line, Neptune disputes fine, and more
This article was originally published in The Tan Sheet
Executive Summary
CDC study calls for safer cough/cold delivery; USPlabs toes FDA line; Neptune disputes workplace safety fine; FDA postpones OTC eyewash hearing; and more In Brief.
You may also be interested in...
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
USPlabs executives, others plead guilty to felony charges stemming from marketing unsafe products labeled as supplements but containing DMAA and linked to hepatitis. Blackstone Labs and other firms indicted on felony charges following FDA investigation for marketing DMBA-containing products. "It's all very welcome news, but I'm not sure this is going to change the overall environment," says Pieter Cohen, a physician who advocates for tighter regulation of supplement manufacturing and marketing.
Flow Restrictors Limit Children’s Access To Drugs; Standards Needed
Only 6% of children emptied medicine bottles with flow restrictors in 10 minutes, compared to 82% who emptied bottles with incompletely closed child-resistant caps within two minutes, a CDC study shows. But researchers and stakeholders suggest waiting for industry standards to implement flow restrictors.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.